• Fellow of the Academy of Translational Medicine 2016
• PhD in Medicine 2007
• Membership of The Royal College of Surgeons of England 1999
• MBChB 1995

Rik Bryan qualified in Medicine at the University of Birmingham and subsequently entered surgical training. After completing a PhD in bladder cancer biology he became a higher surgical trainee in Urology. After 4-years as a Specialist Registrar, Rik left clinical urology to assist with the set-up of the Bladder Cancer Prognosis Programme (BCPP) in the Department of Public Health, Epidemiology and Biostatistics at the University of Birmingham, and was then subsequently appointed as a Senior Research Fellow in the School of Cancer Sciences. Rik is now the Chief Investigator of BCPP, which incorporates the SELENIB clinical trial.

Rik has an interest in all aspects of bladder cancer research and leads a multidisciplinary group with a focus on translation. The particular interests of the Bladder Cancer Group include cancer genomics/epigenomics, urinary biomarkers, novel therapeutics/technologies/devices, and clinical and epidemiological research. Rik has a track record of publication in all of these areas.

The group also has an interest in upper tract urothelial cancer, and Rik is the Chief Investigator of POUT-T, the translational study linked to the POUT trial.

• Intercalated BMedSci
• MRes
• PhD

• Genomics and epigenomics, and associated biomarkers for non-invasive diagnosis and prognostication
• Novel genomic platforms and approaches
• Proteomics and urinary protein biomarkers
• Novel therapeutics, technologies and devices and associated clinical trials
• Tumour immunology and BCG mechanisms of action
• Clinical, epidemiological and health economic research.

Aside from the research carried out at the University of Birmingham, the Bladder Cancer Group also has a number of important national and international collaborations with other bladder cancer investigators, including Professor Maurice Zeegers (Maastricht), Professor John Kelly (UCL), Professor Bart Kiemeney (Radboud), Professor Chris Probert (Liverpool), Dr Anne Kiltie (Oxford) and Professor Chas Bountra (Oxford).

Aside from his bladder cancer research at the University of Birmingham, Rik also fulfils a number of other roles:

• Member of the University of Birmingham’s Clinical Trials Oversight Committee (CTOC)
• Member of the Bladder GeCIP, 100,000 Genomes Project
• Trustee of the charity Action Bladder Cancer UK
• Member of the T2 and Below Subgroup (TABS) of the NCRI Bladder & Renal Clinical Studies Group
• Council Member and current Honorary Secretary of The Royal Society of Medicine Section of Urology
• Member of the Trial Management Group of the Peri-Operative Chemotherapy versus Surveillance in Upper Tract Urothelial Cancer (POUT) trial
• Member of the Trial Management Group of the Clinical Research Office of the Endourology Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection (TURBT) versus conventional white light-assisted TURBT in primary non-muscle-invasive bladder cancer patients.